Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a poster presented here ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an ...

KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...

As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

DME is a leading cause of vision loss in people with diabetes, but early diagnosis and treatment can help preserve vision. Diabetic macular edema can make everyday tasks like reading, driving ...

This swelling is often caused by a buildup of fluid called edema. When just one leg is affected, an infection or chronic condition like arthritis may be at work. Treatment depends on the underlying ...

The following is a summary of “Origin of YouTube videos on hereditary angioedema matters,” published in the March 2025 issue of Allergy, Asthma & Clinical Immunology by Korkmaz et al. Researchers ...

A growth factor-stimulating gene therapy did not improve outcomes with vascularized lymph node transfer (VLNT) for breast cancer-related lymphedema in a small randomized trial, that added to evidence ...

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue. This treatment is already approved for both diabetic macular ...